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ABSTRACT
Obstructive jaundice (icterus) was an emergency situation in gastroenterology. Endoscopic retrograde 
cholangiopancreatography (ERCP) was a nonsurgical approach to release obstruction, mostly in common bile 
duct. Nowadays, this procedure was become frequently used in daily practice, but several complications also 
emerging. One of the severe complication was Post-ERCP Pancreatitis (PEP). Since it has a high mortality 
and morbidity, and also reduce patient quality of life, several approaches have been developed to reduce its 
incidence. In general, approaches consist of patient identi¿cation, ef¿cient procedure, until pharmacological 
agent prevention. Although there were still contradiction among these, careful approach should be considered 
for each patients for a better outcomes. 
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ABSTRAK
Ikterus obstruktif merupakan masalah darurat di bidang gastroenterology. Endoscopic retrograde 
cholangiopancreatography (ERCP) merupakan prosedur non-bedah untuk melepas sumbatan yang sering 
ditemukan pada duktus biliaris. Saat ini, prosedur tersebut menjadi rutin dilakukan pada praktik keseharian, 
namun beberapa komplikasi juga terjadi. Salah satu komplikasi yang parah adalah pankreatitis post-ERCP. 
Oleh karena tingginya mortalitas dan morbiditas, juga menurunkan kualitas hidup pasien, beberapa upaya telah 
dikembangkan untuk mengurangi insidensi pankreatitis ini. Secara umum, upaya dilakukan melalui identi¿kasi 
pasien, tindakan prosedur yang e¿sien, serta medikamentosa. :alaupun masih ada kontradiksi di antara hal 
tersebut, upaya yang hati-hati seharusnya dapat dipertimbangkan untuk setiap pasien untuk hasil yang lebih baik. 
Kata kunci: post-endoscopic retrograde cholangiopancreatography (post-ERCP), pankreatitis, pencegahan
INTRODUCTION 
Obstructive jaundice (icterus) was still an important 
emergency in gastroenterology. Both acute and chronic 
bile obstruction could lead to several complications 
such as cholangitis and sepsis. Endoscopic retrograde 
cholangiopancreatography (ERCP) was a non-surgical 
approach to release obstruction in common bile duct. 
Nowadays, this procedure was become frequently used 
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in daily practice, but severe complication was still 
present from mild to severe. Among the complications 
was acute pancreatitis that raise mortality and 
morbidity in patients. 
Post ERCP pancreatitis was related to dif¿culty, 
technique, and skills of the endoscopist. Post ERCP 
pancreatitis (PEP) incidence was about 2-9% and in 
several center could as high as 30% because of different 
de¿nition of pancreatitis.1 PEP could be mild (90%) to 
severe (pancreatitis necroticans, multiorgan failure, and 
death). <et, there were several de¿nition of PEP with 
different severity of pain and duration as its factors. 
Some therapy was used to prevent the developing 
of PEP, such as right patient selection, pancreatitis 
prophyla[is, and more advanced skills during 
procedure. Early detection of PEP was also studied 
to develop a better outcomes in patients management. 
This review will discuss about diagnosis and 
prevention of post ERCP pancreatitis comprehensively 
from pharmacological to various ERCP technique. 
(SLGHPLRORJ\ DQG 'LDJQRVLV RI 3RVW(5&3
Pancreatitis
Pancreatitis was a severe complication of ERCP 
procedure in obstructive jaundice patients. In general, 
pancreatic enzymes increase after procedure but could 
not be classi¿ed as pancreatitis. Based on Atlanta Criteria, 
PEP could be diagnosed if (1) New and progressive 
abdominal pain; (2) New or longer hospitalization; (3) 
Increase serum amylase by 3 times or more from upper 
norma limit in 24 hours after ERCP procedure.2
Based on diagnostic criteria above, PEP incidence in 
a Meta Analysis study involving 21 prospective study 
was about 1,6-15% (mean 3,5%).3 On the other hand, 
Cotton et al proposed another diagnostic criteria: (1) 
Increase serum amylase more than 3 times from upper 
normal limit; (2) Typical abdominal pain for pancreatitis; 
(3) Abdominal pain more than 24 hours; (4) A severe 
pain that need hospitalization.4 Cotton et al also classi¿ed 
patients into several pancreatitis grading based on its 
severity, as shown in Table 1. Pancreatitis severity based 
on Atlanta Criteria was shown in Table 2. 
3RVW(5&33DQFUHDWLWLV3DWKRJHQHVLV
8ntil nowadays, the e[act mechanism of PEP 
development was still unknown. Several hypothesis 
have been proposed by e[perts, such as mechanical 
trauma in papillae orificium, hydrostatic damage, 
and enzymatic damage caused by proteolytic enzyme 
activated form duodenum.4 Mechanical trauma 
7DEOH3RVWHQGRVFRSLFUHWURJUDGHFKRODQJLRSDQFUHDWRJUDSK\
(PEP) severity grading4
Mild Moderate Severe
 – Elevation in serum 
amylase concentration 
more than three times 
upper normal level
 – At least 24 hours after 
the procedure
 – Requiring admission 
or prolongation of 
planned admission to 
two to three days
 – Hospitalization 
of four to ten 
days
 – Hospitalization 
for more than ten 
days,
 – Patients with 
hemorrhagic 
pancreatitis,
 – Patients with 
newly developed 
phlegmon or 
pseudocyst, or
 – Patients 
who require 
intervention such 
as percutaneous 
drainage or 
surgery
7DEOH3RVWHQGRVFRSLFUHWURJUDGHFKRODQJLRSDQFUHDWRJUDSK\
3(3VHYHULW\JUDGLQJEDVHGRQ$WODQWDFODVVL¿FDWLRQ4
Mild Moderate Severe
 – Lacking both 
organ failure and 
local or systemic 
complications
 – Transient organ 
failure (organ 
failure < 2 days)
 – Local 
complications*, 
and/or 
exacerbation 
of co-existent 
disease
 – Presence of 
persistent organ 
failure ( 2 days)
*Local complications include acute peripancreatic Àuid collections, pseudocyst, 
acute pancreatic or peripancreatic necrotic collection, and walled-off necrosis
damaging papilla ori¿cium that lead to Oddi sphincter 
spasm or pancreatic ori¿cum edema, so that pancreatic 
duct obstruction happened and lead to increase 
in pancreatic enzyme and finally inflammation. 
This damage could occur as a result from dif¿cult-
canulation ERCP that need a longer time, or a 
recanulation procedure. Beside that, thermal trauma 
from electrocautery during spinchterectomy could also 
lead to those damage.5
Hydrostatic damage was possible in overinjection 
in pancreatic duct that disrupt cell membrane and tight 
junction. As a result, a backÀow of intraductal secrete 
to interstitial tissue cause pancreatitis.6 Chemical 
trauma from ionic contrast with high osmolarity was 
another cause of pancreatic tissue damage. Otherwise, 
there were no meta analysis yet to show the relation 
between contrast and non-contrast media. This 
chemical trauma cause premature proteolytic enzymes 
activation that cause pancreatic cell autodigestion with 
reduced protective effect of acinar cell secretion, so 
that pancreatitis was developed.4
5LVN)DFWRUVRI3RVW(5&33DQFUHDWLWLV
Several risk factors was present in PEP, involving 
patient, procedural, and operator factors. Based 
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on meta analysis by Masce et al from 15 studies, 
it can be concluded that those risk factors was:7 
(1) patient factors: women (RR = 2.23), SOD (RR 
= 2.23), previous pancreatitis (RR = 2.46), young 
age (< 60 years old), normal bilirubin (OR = 1.89); 
(2) Procedural factors: sphinchterectomy precut 
(RR = 2.71), pancreatic duct injection (RR = 2.21), 
balloon dilatation in intact sphincter , pancreatic 
sphicnterectomy, dif¿cult cannulation (6-15 [ try, OR 
= 3.41), papilla minor sphicnterectomy (OR = 3.82), 
pain during ERCP (OR = 1.95), and ampulectomy; and 
(3) operator factor: trainee involvement. The more risk 
factors present, the highest PEP incidence possibility. 
High risk patient identi¿cation was an important 
thing to do in PEP prevention. Patient with more than 
one risk factors should be given detailed e[planation 
and counseling before the procedure. Other approach 
such as MRSP or EUS to reduce PEP risk was prioritize 
to replace diagnostic ERCP procedure. 
3UHYHQWLRQRI3RVW(5&33DQFUHDWLWLV3(3
In daily practice, there were so many treatments 
developed to reduce PEP in obstructive jaundice 
patients, from careful patients identification, 
pharmacological therapy, until various technique 
during ERCP. Unfortunately, there were no strong 
evidence which approach has been successful and 
effective to prevent PEP. 
Endoscopist Prevention
This risk of pancreatitis was strongly related to 
endoscopist skill during ERCP. In referral center, 
which ERCP was done more routinely, dif¿culty during 
cannulation was commonly found and impact on the 
higher pancreatitis incidence. The presence of trainee 
was also an important factors of PEP incidence. Based 
on prospective study by Williams et al and Testoni et al, 
it can be concluded that PEP incidence was not correlate 
to cases number done by endoscopist in a referral center.7
7(&+1,&$/ 35(9(17,21 2) 3267(5&3
PANCREATITIS
Standard Canulation 
Standard biliary cannulation was using catheter 
with or without soft tip guidewire. Contrast then 
injected through catheter could be unintendedly enter 
pancreatic duct. A guidewire insertion to pancreatic 
and common bile duct could reduce the risk of contrast 
injection entering pancreatic duct with Àuoroscopy. 
A systematic review study by Cheung et al from 7 
RCTs showed a reduced pancreatitis risk compared to 
contrast injection using guidewire (RR = 0.38; 95% 
CI: 0.19-0.76).7
Pancreatic Stent as Prophylaxis
The rational use of pancreatic stent was based on 
the principal that mechanical trauma will cause a Àow 
obstruction and and inÀammation in pancreas. A Meta 
Analysis showed a reduced risk in 13.3% and NNT of 8 
to prevent 1 patient develop PEP with this technique.4 
Menawhile, pancreatic stent placement has a higher 
risk of occlusion, migration, perforation, infection, 
erotion, and the need of re-endoscopy for evaluation 
and removal of the stent. A pancreatic duct stricture 
was also a possible complication. Therefore, this 
approach was not yet been choosen as an alternative 
for PEP prevention.
Pancreatic Duct Injection
Pancreatic duct injection was a multiple injection 
that correlate to the risk of PEP. Until now, ERCP was 
also done as diagnostic tool for neoplasms, such as 
pancreatic cyst, mainly to know any connection between 
cyst and biliary tract. Low osmolarity contrast was more 
recommended than high omsolarity. By reduce injection 
frequency, risk of PEP was predicted to be lower.7
3DQFUHDWLF*XLGHZLUH$VVLVWHG%LOLDU\&DQQXODWLRQ
Pancreatic guidewire placement was effective to 
ensure biliary tract access by straightening ampula 
and avoid pancreatic duct cannulation. This technique 
was mainly used in hard-cannulated patients or 
coincidentally recannulated pancreatic duct. Pancreatic 
stent placement after guidewire was recommended to 
reduce PEP incidence.7
Perendoscopic Sphincterectomy
Thermal damage caused by cauter could lead to 
ampula edema and obstruct pancreatic duct. Endocut 
was related to reduced risk of PEP by reducing edema 
in patients. Eventhough, bleeding risk was signi¿cantly 
increased. Therefore, there were still some pro and 
contra to done endocut.7
Balloon Sphincteroplasty
This technique was used to e[tract any stone via 
endoscopic sphincterectomy. The advantage was the 
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Oddi sphincter was preserved, especially for young 
patients, and also lower bleeding risk. Instead, several 
studies showed an increased risk of PEP in patients 
underwent this balloon sphincteroplasty. Yet, this 
technique was not concluded as a risk of PEP, e[ept 
combined with perendoscopic sphincterectomy.7
1HHGOHNQLIH3UHFXW
Precutting using needle knife was needed 
in a condition where standard cannulation was 
unsuccessful. This technique was strongly correlate 
to PEP. Meanwhile, this technique was also overcome 
with its less multiple cannulation possibility. Manes et 
al studied 151 patients with hard-cannulating after 10 
minutes and compared to precut or standard cannulation 
with incidence was found lower in precut group (2,6% 
vs. 14.9%; p = 0.0008). But, a study by Cennamo et 
al investigate precut and standard cannulation result 
during hard-cannulation for 5 minutes showed no 
difference among two groups in PEP incidence.7
Oddi Sphincter Mannometry 
Oddi Sphincter Mannometry was a gold standard 
for sphincter dysfunction e[amination. This sphincter 
dysfunction was correlate to high PEP incidence in 
patient. Pancreatitis risk could be reduced if pancreatic 
manometry was done before to know any SOD in 
patient, so that early pancreatic stenting could be done. 
Pharmacological Prevention
Ideal pharmacological therapy was effective to 
reduce PEP incidence and could be administerd in short 
time, well-tolerated, and low side effect. 
AntiinÀammatory drugs was a potent inhibitor for 
inÀammatory mediators, mainly prostaglandin and 
phospholipase A2 which related to acute pancreatitis. 
Elmunzer et al showed in a meta analysis involving 4 
RCTs that NSAIDs per rectum was effective to reduce 
PEP incidence. Rectal indometachin before procedure 
or diclofenac after the procedure was effective. Oral 
administration of the drugs was not effective since it 
has a longer time to reach highest blood concentration. 
Besides, first-pass metabolism also reduce its 
bioavailability. ESGE recommended rectal diclofenac 
100 mg to be administered just before the procedure.8
Glyceryl trinitate (GTN) was a smooth muscle 
rela[ant thant could reduce basal pressure of Oddi 
sphincter, administered sublingually or as a transdermal 
patch. An evaluation by Kaffes et al showed that 
there were no signi¿cant difference between therapy 
and placebo groups on PEP incidence, although 
Moreto et al showe a signi¿cant improvement in 144 
patients administered GTN. Until present, this drug 
administration was not recommended yet in PEP 
prevention.7
Ceftazidime was also used hypothese as its 
antimicrobial effect would prevent PEP development. 
Administration of 26 Ceftazidime 30 minutes before 
ERCP procedure could reduce PEP incidence in 
160 patients of a trial, but this accuracy was stilll 
questionable. 
Somatostatin and octreotide was also a potent 
inhibitor of pancreatic e[ocrine secretion that have 
an important rote in PEP pathogenesis. There were 2 
meta analysis that investigate the role of both drugs. 
Andriulli et al studied 9 study in his meta analysis and 
showed a nonsigni¿cant effect of Somatostatin in PEP 
prevention (OR = 0.73; 95% CI: 0.54-1.006). There 
also studies to investigate both short-term Somatostatin 
infusion (< 6 hours) and long-term infus¿on (! 12 
hours) in patients, but unfortunately it also give an 
insignificant result. Therefore, ESGE has not yet 
recommended ocreotide as PEP prevention, but further 
studies was developed to investigate its ef¿cacy on 
> 0,5 mg dosage.8
Protease inhibitor was also used as assumed 
that acute pancreatitis was happened because of 
intracelullar tripsin activation, and could be precented. 
Several known protease inhibitor drugs was Gabe[ate, 
Ulinastatin, and Nafamostat mesylate. Several RCTs 
given an contradiction result. Xiong et al showed a less 
signi¿cant effect of PEP in 97 patients given gabe[ate 
)LJXUH3KDUPDFRORJLFDOUHJLPHQWXVHGWRSUHYHQWSRVW(5&3
pancreatitis (PEP)7
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30 minutes before ERCP, while Manes et al showed a 
signi¿cant result in gabe[ate given 1 hours before or 
after the procedure. Meanwhile, further meta analysis 
showed an insigni¿cant result of Gabe[ate. This was 
possible because of its very short half-life time (55 
seconds) while there were need a continuos infusion 
for prevention. Differ to Gabe[ate, Ulinastatin has a 
longer half-life time (35 minutes) and could be given 
as bolus intravenous. Administration of Ulinastatin 
150.000 Unit before ERCP was signi¿cantly reduce 
PEP incidence (2.9% vs. 7.4%, p = 0.041).9 
Nafomastat showed a signi¿cant reduction in PEP 
if given 1 hours before ERCP and continued for the 
ne[t 24 hours (p = 0.018). Yet, protease inhibitor still 
rarely used and have a higher cost to be given routinely 
in pre-ERCP patients. 
Allopurinol, a [hantine o[idase inhibitor, would 
catalyze hypo[hantine to [hantine that its end 
product was free radical. This free radical would 
trigger capillary endothelial damage and result in 
acute pancreatitis. Although animal studies showed 
a good result, some clinical trial did not showed the 
same result. Administration of 600 mg Allopurinol 15 
hours before ERCP and 3 hours before ERCP showed 
a good result (2.3% vs. 9.4%; p = 0.04), while and 
administration at 4 and 1 hours before ERCP showed 
no differences to placebo.7
Oral prednisone with 40 mg dose did not reduce PEP 
incidence in 1115 patients at a clinical trial. Heparin 
have a protease inhibiting effect in both plasm and 
tissue, but studies showed that LMWH administration 
before ERCP did not reduce PEP incidence (8.1% vs. 
8.8%; p = 0.87).7
N-acetylcystein was an anti-free-radical that have 
an important role in pancreatitis pathogenesis. A study 
by Katsinelos et al and Milewski et al showed no 
difference of PEP incidence in patients administered 
N-acetylcystein compared to placebo (12.1% vs. 9.6%; 
p > 0.05 and 7.3% vs. 11.8%; p = NS).7 The summary 
of all pharmacologic therapy in PEP prevention was 
shown in Table 4. 
In general, prevention of PEP could be divided 
into 5 main area: (1) Correct patients identi¿cation; 
(2) Risk strati¿cation for patients undergo ERCP; 
(3) Atraumatic and ef¿cient procedure technique, 4) 
pancreatic stent as prophyla[is; (5) Pharmacological 
prevention.11
CONCLUSION
Pancreatitis was still a main complication of 
ERCP and further could reduce patient quality of 
life, morbidity, and mortality. Several approaches 
have been developed to reduce its incidence from 
7DEOH3KDUPDFRORJLFDJHQWVDQGLWVHIIHFWRISRVW(5&3SDQFUHDWLWLV3(3SUHYHQWLRQ7
Drug Suggested way of action Effective in prospective RCT
Calcium channel blockers
Nitroglycerine
Topical lidocaine spray
Antibiotics
Ocreotide
Somatostatin
Corticosteroids
Allupurinol
N-acetylcysteine
Platelet activating factor inhibitors
Interleukin-10
Heparin
Gabexate
Diclofenac (NSAIDs)
Sphincter spasm
Infection
Pancreatic secretion
InÀammation cascade
No
ConÀicting data
No
ConÀicting data, need for more trials
ConÀicting data
ConÀicting data
No
ConÀicting data
No
No
ConÀicting data
ConÀicting data
ConÀicting data
Yes in only one study, need for more trials
NSAIDs non-steroidal anti-inÀammatory drugs RCT randomized control trial
7DEOH0HFKDQLVPRIDFWLRQRIVHYHUDOGUXJVIRUSRVW(5&3SDQFUHDWLWLV3(3SUHYHQWLRQ10
Postulated mechanism of action Agents
Interruption of inÀammatory cascade
Reduction of pancreatic enzyme secretion
Inhibition of protease activity
Reduction of sphincter of-Oddi pressure
Prevention of infection
Anti-oxidants
Anti-metabolites
NSAIDs, steroids, interleukin-10, allopurinol, adrenaline spray, 
pentoxifylline, platelet-activating factor-acetylhidrolase, semapimod, 
aprepitant, risperidone
Octreotide, somatostatin, calcitonin
Gabexate mesilate, heparin, ulinastatin, nafamostat, magnesium 
sulphate
Nitroglycerin, nifedipine, botulinum toxin, lidocaine, secretin, 
phosphodiesterase inhibitor type 5
Antibiotics
Beta-carotene, N-acetylcysteine, sodium selenite
5-Àuorouracil
NSAIDs non-steroidal anti-inÀammatory drugs
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patient identification, efficient procedure, until 
pharmacological agent prevention. Since several 
studies did not showed an absolute signi¿cant result, 
every case should be identified carefully, so that 
pancreatitis incidence as ERCP complication in 
obstructive jaundice patients could be reduced.  
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Figure 1. PEP prevention diagram11
